| Metric | Value ($ M) | Q1 FY25 |
|---|---|---|
| Revenue | 722.52 | 3.9% |
| Total Income | 722.52 | 3.9% |
| Expenditure | 580.75 | 2.4% |
| PBT | 80.18 | 113.9% |
| Net Profit | 62.26 | 410.3% |
| OPM | 19.62% | 5.19pp |
| NPM | 8.62% | 6.86pp |
| EPS | 0.20 | 400.0% |
Amneal Reports Preliminary Q1 2026 Results; Raises FY2026 Guidance
22 Apr 2026 · 22 Apr, 3:52 pm
Summary
Amneal Pharmaceuticals reported preliminary first quarter 2026 financial results, showing a 4% increase in consolidated net revenue to $723 million. Specialty net revenue saw a significant increase of 23%, reaching $133 million. Net income increased substantially by 217% to $78 million, and adjusted EBITDA rose by 19% to $202 million. Due to the strong start to the year, Amneal is raising its full year 2026 standalone guidance for adjusted EBITDA and adjusted diluted EPS.
Key Highlights
- 1
Amneal's consolidated net revenue for Q1 2026 reached $723 million, a 4% increase compared to $695 million in the prior year.
- 2
Specialty net revenue increased by 23% to $133 million in Q1 2026, driven by CREXONT® and BREKIYA®.
- 3
Net income for Q1 2026 was $78 million, a 217% increase compared to $25 million in the prior year.
- 4
Adjusted EBITDA for Q1 2026 increased by 19% to $202 million compared to $170 million in the prior year.
- 5
The company is raising its full year 2026 adjusted EBITDA guidance to $740 million - $770 million.
- 6
Amneal is raising its full year 2026 adjusted diluted EPS guidance to $0.95 - $1.05.
Management Comments
Chirag Patel
As biosimilar adoption accelerates and the industry enters an unprecedented period of biologic loss of exclusivity, we see a compelling opportunity to establish leadership and scale in a rapidly expanding market.
Chirag Patel
With Kashiv, Amneal becomes a fully integrated global biosimilars leader at the forefront of the next wave of U.S. affordable medicines. This acquisition is a natural next step in our strategy to build a leading, diversified biopharmaceutical company, and we are confident it will drive accelerated growth and long-term value creation.
Chintu Patel
This acquisition establishes Amneal as a fully integrated global biosimilar platform at scale. By combining Kashiv’s deep R&D and manufacturing capabilities with our commercial strength, we are creating a differentiated platform well-positioned to deliver a strong and consistent cadence of biosimilar launches going forward. Together, we will expand access to high-quality, affordable biologic medicines for patients while driving long-term growth.
Dr. Sandeep Athalye
We are thrilled to combine Kashiv’s highly complementary portfolio and capabilities with Amneal at this critical inflection point for the biosimilar market, particularly in the U.S. Our companies share a deep-rooted commitment to high-quality, complex medicines, and this transaction builds on the meaningful work we have accomplished through our collaboration of more than ten years. We look forward to building on our proven track record of product approvals and advancing our biosimilars pipeline as we work together to expand patient access to life-changing therapies.
Chirag and Chintu Patel
Amneal delivered a very strong start to 2026, reflecting the strength of our diversified business and multiple growth drivers across the portfolio. Our Specialty business continues to perform exceptionally well, led by CREXONT® and the recent launch of BREKIYA® autoinjector, alongside a strong cadence of key launches in Affordable Medicines. We are entering the Kashiv transaction from a position of strength, at a time when we see an extended period of accelerated growth ahead with no shortage of opportunities across our core businesses. Combined with our very strong first quarter results, we are pleased to increase our full year 2026 guidance
Informational and educational content only. Not investment advice.